Literature DB >> 34666235

Host characteristics associated with serologic inflammatory biomarkers in women.

Sophia S Wang1, Charlie Zhong2, Marta Epeldegui3, Sarah Nunes4, Larry Magpantay3, Jessica Clague DeHart5, Susan Hurley6, Debbie Goldberg7, Elena Martinez8, James V Lacey9, Otoniel Martinez-Maza3, Peggy Reynolds7.   

Abstract

BACKGROUND: There is growing evidence that exposure to low-grade inflammation may be associated with adverse health outcomes.
METHODS: We conducted a cross-sectional study within the California Teachers Study prospective cohort, among female participants who had completed a questionnaire that asked about their health behaviors (e.g., diabetes, physical activity, body mass index, medication use) and who had donated blood within a year of their questionnaire. 822 women with stored serum were evaluated for 16 immune biomarkers. In addition, four immune pathways were constructed: Th1, pro-inflammatory/macrophage activation, B-cell activation, and T-cell activation. Odds ratios (ORs) and 95% confidence intervals (CI) for the association between host characteristics and immune biomarkers were assessed using logistic regression models. RESULT: Compared to women of a normal BMI, obese women (>30 kg/m2) were positively associated with sTNFR2, CD27, IL6, CXCL13, sIL-2Rα, and IL6Ra levels above the median, with odds ratios ranging from 1.5 to 6.0. The pro-inflammatory/macrophage activation pathway was positively associated with diabetes (OR = 2.12, 95% CI = 1.14-3.95), fueled by individual associations between diabetes and sTNF-R2, TNFα and sCD27. Physical activity was inversely associated with sTNF-R2, TNFα, CXCL13, IL6, IL10, and IFN-γ levels, particularly for the highest category of activity (5.88+ hours/week) (ORs = 0.32-0.69). In pathway-based analyses, the Th1 pathway which includes decreased levels of IL4 and IL10 was positively associated with elevated physical activity (OR = 1.5). In contrast, the pro-inflammatory, B- and T-cell activation pathways were positively associated with higher BMI (OR ranging from 1.6 to 3) and inversely associated with increasing levels of physical activity.
CONCLUSIONS: Several host characteristics were associated with circulating levels of immune biomarkers, including markers of inflammation. Further understanding of associations between immune marker profiles with human disease are warranted.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood; Circulating markers; Cross-sectional; Diabetes; Epidemiology; Human; Inflammation; Obesity; Physical activity; Statins

Mesh:

Substances:

Year:  2021        PMID: 34666235      PMCID: PMC8680201          DOI: 10.1016/j.cyto.2021.155726

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  43 in total

Review 1.  Inflammatory biomarkers for predicting cardiovascular disease.

Authors:  Lee Stoner; Adam A Lucero; Barry R Palmer; Lynnette M Jones; Joanna M Young; James Faulkner
Journal:  Clin Biochem       Date:  2013-06-10       Impact factor: 3.281

Review 2.  Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis.

Authors:  Chenxiao Liu; Xiu Feng; Qi Li; Ying Wang; Qian Li; Majian Hua
Journal:  Cytokine       Date:  2016-08-04       Impact factor: 3.861

3.  Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study.

Authors:  S Mirza; Monir Hossain; Christine Mathews; Perla Martinez; Paula Pino; Jennifer L Gay; Anne Rentfro; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Cytokine       Date:  2011-10-28       Impact factor: 3.861

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

Review 5.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study.

Authors:  Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Christie M Ballantyne; David Couper; Alvaro Vigo; Ron Hoogeveen; Aaron R Folsom; Gerardo Heiss
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

8.  Resistance exercise training-induced decrease in circulating inflammatory CD14+CD16+ monocyte percentage without weight loss in older adults.

Authors:  Melissa M Markofski; Michael G Flynn; Andres E Carrillo; Cheryl L H Armstrong; Wayne W Campbell; Darlene A Sedlock
Journal:  Eur J Appl Physiol       Date:  2014-05-16       Impact factor: 3.078

9.  Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study.

Authors:  Laure Dossus; Sabina Rinaldi; Susen Becker; Annekatrin Lukanova; Anne Tjonneland; Anja Olsen; Jakob Stegger; Kim Overvad; Nathalie Chabbert-Buffet; Aida Jimenez-Corona; Francoise Clavel-Chapelon; Sabine Rohrmann; Birgit Teucher; Heiner Boeing; Madlen Schütze; Antonia Trichopoulou; Vassiliki Benetou; Pagona Lagiou; Domenico Palli; Franco Berrino; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Maria-Luisa Redondo; Noémie Travier; Maria-Jose Sanchez; Jone M Altzibar; Maria-Dolores Chirlaque; Eva Ardanaz; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; N Charlotte Onland-Moret; Petra H M Peeters; Goran Hallmans; Eva Lundin; Kay-Tee Khaw; Nicholas Wareham; Naomi Allen; Tim J Key; Nadia Slimani; Pierre Hainaut; Dora Romaguera; Teresa Norat; Elio Riboli; Rudolf Kaaks
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

10.  Elevated Serum TNF-α Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance.

Authors:  Hana Alzamil
Journal:  J Obes       Date:  2020-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.